[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 138 pages | ID: K618542EABFEEN
Global Markets Direct

US$ 2,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Klebsiella Pneumoniae Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Drugs In Development, 2022, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 1, 42, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Klebsiella pneumoniae Infections - Overview
Klebsiella pneumoniae Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Klebsiella pneumoniae Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
Klebsiella pneumoniae Infections - Drug Profiles
Klebsiella pneumoniae Infections - Dormant Projects
Klebsiella pneumoniae Infections - Discontinued Products
Klebsiella pneumoniae Infections - Product Development Milestones
Featured News & Press Releases
Jul 07, 2020: Data published in Ebiomedicine validates novel scientific approach that disarms bacterial defenses to treat or prevent life-threatening infections
Sep 05, 2019: Summit presented in vivo proof of concept data for targeted Enterobacteriaceae antibiotics at ASM/ESCMID Conference
Aug 27, 2019: Vaccine against deadly superbug Klebsiella effective in mice
Aug 20, 2019: Vaxxilon receives grant to develop new prophylactic vaccine
Jul 02, 2019: Appili Therapeutics signs $3M USD grant contract with the United States Department of Defense to develop antibiotics that target superbugs
Apr 03, 2019: Summit’s pipeline expands with series of new mechanism antibiotics targeting Enterobacteriaceae
May 07, 2018: Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
Apr 17, 2018: Arsanis to Present Abstract On ASN300 At The 28th European Congress of Clinical Microbiology And Infectious Diseases
Nov 07, 2017: Appili Therapeutics Receives $1.2M USD from the Department of Defense to Advance Antibiotic Targeting Drug-Resistant Bacteria
Sep 30, 2017: Development of a negamycin analogue targeting the translational machinery in gram-negative drug-resistant pathogens for the treatment of Infections
Apr 20, 2017: Arsanis Presents Data on ASN-300 at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Apr 11, 2017: Appili Therapeutics Receives Funding from the Government of Canada to Support Development of New Antibiotic To Treat Gram-Negative Infections
Jun 17, 2016: Arsanis Presents Data at ASM Microbe 2016 Demonstrating Protection Against Klebsiella pneumoniae using Monoclonal Antibody Technology
Mar 09, 2015: Phico Therapeutics Receives Translation Award to Advance its SASPject PT4 Aimed at Escherichia coli and Klebsiella pneumoniae Towards Clinical Trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Klebsiella pneumoniae Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, 2022
Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Alterity Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Bioversys AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by CHO Pharma Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Clarametyx Biosciences Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, 2022
Klebsiella pneumoniae Infections - Pipeline by Dong-A ST Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Entasis Therapeutics Holdings Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by GSK plc, 2022
Klebsiella pneumoniae Infections - Pipeline by Idorsia Pharmaceutical Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Infextious Therapeutic, 2022
Klebsiella pneumoniae Infections - Pipeline by LimmaTech Biologics AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Linnaeus Bioscience Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Mikrobiomik Healthcare Company SL, 2022
Klebsiella pneumoniae Infections - Pipeline by Nektr Technologies Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, 2022
Klebsiella pneumoniae Infections - Pipeline by Novabiotics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, 2022
Klebsiella pneumoniae Infections - Pipeline by Pedanius Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Planet Biotechnology Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Recce Pharmaceuticals Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, 2022
Klebsiella pneumoniae Infections - Pipeline by Seres Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Spexis AG, 2022
Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Klebsiella pneumoniae Infections - Pipeline by Techulon Inc, 2022
Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, 2022
Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Centre, 2022
Klebsiella pneumoniae Infections - Dormant Projects, 2022
Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..1)
Klebsiella pneumoniae Infections - Dormant Projects, 2022 (Contd..2)
Klebsiella pneumoniae Infections - Discontinued Products, 2022

LIST OF FIGURES

Number of Products under Development for Klebsiella pneumoniae Infections, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022


More Publications